Related Experiment Videos
Tc-99m sestamibi and In-111 pentetreotide uptake in metastatic papillary thyroid carcinoma
J Lee1, J A Cutrone, C S Marcus
1Department of Radiology, Medicine Harbor-UCLA Medical Center, Torrance 90509, USA.
Clinical Nuclear Medicine
|October 1, 1995
Abstract:
Approximately 25% of metastatic and recurrent differentiated (papillary and follicular) thyroid carcinoma do not concentrate 1-131 Nal. In such cases, diagnosis can be attempted with other radiopharmaceuticals. The authors present a case of recurrent papillary thyroid carcinoma that was well visualized with Tc-99m sestamibi and In-111 pentetreotide; but only poorly visualized by I-131 Nal.